Xavier CastellsaguéKevin A. AultF. Xavier BoschDarron BrownJack CuzickDaron G. FerrisElmar A. JouraSuzanne M. GarlandAnna R. GiulianoMauricio Hernandez-AvilaWarner HuhOle Erik IversenSusanne K. KjaerJoaquin LunaJoseph MonsonegoNubia MuñozEvan MyersJorma PaavonenPunnee PitisuttihumMarc StebenCosette M. WheelerGonzalo PerezAlfred SaahAlain LuxembourgHeather L. SingsChristine VelicerInstitut d'Investigació Biomedica de BellvitgeUniversity of Kansas Medical CenterIndiana University School of Medicine IndianapolisBarts and The London School of Medicine and DentistryAugusta UniversityMedizinische Universitat WienMurdoch Children's Research InstituteMoffitt Cancer CenterInstituto Nacional de Salud PublicaUniversity of AlabamaHelse Bergen Haukeland University HospitalKøbenhavns UniversitetFundación Universitaria SanitasInstitut du ColNational Institute of CancerDuke University Medical CenterHelsinki University HospitalMahidol UniversityInstitut National de Sante Publique Du QuebecUniversity of New Mexico Health Sciences CenterMerck & Co., Inc.Universidad del Rosario2018-12-112019-03-142018-12-112019-03-142016-12-01Papillomavirus Research. Vol.2, (2016), 61-69240585212-s2.0-84961675401https://repository.li.mahidol.ac.th/handle/123456789/40789© 2016 The Authors. Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1016/j.pvr.2016.03.002